NLRP3 and diabetes mellitus: Drugs such as glyburide, a sulfonylurea used in diabetes treatment, and brilliant blue G, an antagonist of P2X purinergic receptor 7 (P2X7) receptors, have been shown to inhibit the activation of NLRP3 and reduce the secretion of pro-inflammatory cytokines [98].